Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor-positive Advanced Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07340619
What this trial is testing

Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.

Who this might be right for
Metastatic (Stage IV) Melanoma
UNICANCER 51
Not applicableLooking for participantsNCT07347600
What this trial is testing

Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Locally Advanced Breast CancerMetastatic Breast Cancer
Hoffmann-La Roche 500
Testing effectiveness (Phase 2)Active Not RecruitingNCT06590857
What this trial is testing

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Who this might be right for
Metastatic Breast CancerHER2-negative Breast CancerER+ Breast Cancer+7 more
RayzeBio, Inc. 16
Testing effectiveness (Phase 2)Ended earlyNCT03858972
What this trial is testing

Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC

Who this might be right for
Breast Cancer
Odonate Therapeutics, Inc. 152
Not applicableLooking for participantsNCT07227831
What this trial is testing

A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer

Who this might be right for
HER2-negative Breast CancerHormone Receptor Positive TumorAdvanced Breast Cancer+1 more
Barbara Ann Karmanos Cancer Institute 82
Testing effectiveness (Phase 2)Active Not RecruitingNCT05262400
What this trial is testing

Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Who this might be right for
Breast CancerSolid Tumors
Pfizer 235
Testing effectiveness (Phase 2)Active Not RecruitingNCT04524000
What this trial is testing

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 24
Large-scale testing (Phase 3)Looking for participantsNCT07205822
What this trial is testing

Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 100
Not applicableStudy completedNCT05173103
What this trial is testing

Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer

Who this might be right for
Advanced Breast CancerHormone Receptor Positive Breast CarcinomaHER2-negative Breast Cancer
University of Milano Bicocca 254
Large-scale testing (Phase 3)Active Not RecruitingNCT02221999
What this trial is testing

Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients

Who this might be right for
Tubular Breast CancerMucinous Breast CancerInvasive Ductal Breast Cancer+1 more
RenJi Hospital 250
Testing effectiveness (Phase 2)Study completedNCT02028364
What this trial is testing

Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women

Who this might be right for
Breast Cancer
Jules Bordet Institute 55
Early research (Phase 1)Ended earlyNCT06878248
What this trial is testing

Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer MetastaticLocally Advanced Breast Cancer (LABC)Malignant Neoplasm of Breast+3 more
Calibr, a division of Scripps Research 10
Early research (Phase 1)Study completedNCT03251378
What this trial is testing

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers

Who this might be right for
Advanced Solid TumorsMetastatic Colon CancerMetastatic Breast Cancer+4 more
Hutchison Medipharma Limited 129
Not applicableUnknownNCT01655004
What this trial is testing

Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PD

Who this might be right for
Breast Carcinoma
National University Hospital, Singapore 110
Testing effectiveness (Phase 2)Study completedNCT04699630
What this trial is testing

U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast Cancer
SCRI Development Innovations, LLC 121
Not applicableUnknownNCT05000736
What this trial is testing

Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC

Who this might be right for
Hormone Receptor Positive Advanced Breast Cancer
Chinese Academy of Medical Sciences 600
Early research (Phase 1)Ended earlyNCT02964507
What this trial is testing

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

Who this might be right for
Neoplasms
GlaxoSmithKline 124
Testing effectiveness (Phase 2)Ended earlyNCT02395627
What this trial is testing

Reversing Therapy Resistance With Epigenetic-Immune Modification

Who this might be right for
Breast Neoplasms
University of California, San Francisco 38
Large-scale testing (Phase 3)Ended earlyNCT03439046
What this trial is testing

Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 287
Testing effectiveness (Phase 2)Study completedNCT03045653
What this trial is testing

Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer

Who this might be right for
Breast Cancer Metastatic
Sun Yat-sen University 30
Next Page